1. Home
  2. MKTW vs VERU Comparison

MKTW vs VERU Comparison

Compare MKTW & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$14.50

Market Cap

39.1M

Sector

Technology

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.39

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
VERU
Founded
1999
1971
Country
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.1M
41.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKTW
VERU
Price
$14.50
$2.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$20.00
$22.50
AVG Volume (30 Days)
12.1K
106.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.08
$2.10
52 Week High
$21.74
$7.40

Technical Indicators

Market Signals
Indicator
MKTW
VERU
Relative Strength Index (RSI) 37.80 48.27
Support Level $13.92 $2.22
Resistance Level $15.79 $2.50
Average True Range (ATR) 0.65 0.19
MACD -0.19 -0.02
Stochastic Oscillator 19.05 31.67

Price Performance

Historical Comparison
MKTW
VERU

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: